Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

C. Confavreux; P. O'Connor; G. Comi; M.S. Freedman; A.E. Miller; T.P. Olsson; J.S. Wolinsky; T. Bagulho; J.L. Delhay; D. Dukovic; F. Barkhof; P. Truffinet; L. Kappos

doi:https://doi.org/10.1016/S1474-4422(13)70308-9

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

C. Confavreux, P. O'Connor, G. Comi, M.S. Freedman, A.E. Miller, T.P. Olsson, J.S. Wolinsky, T. Bagulho, J.L. Delhay, D. Dukovic, F. Barkhof, P. Truffinet, L. Kappos

Radiology and Nuclear Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

434 Citations (Scopus)

Original language	English
Pages (from-to)	247-256
Journal	Lancet neurology
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/S1474-4422(13)70308-9
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/S1474-4422(13)70308-9

Cite this

Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J. L., Dukovic, D., Barkhof, F., Truffinet, P., & Kappos, L. (2014). Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet neurology, 13(3), 247-256. https://doi.org/10.1016/S1474-4422(13)70308-9

@article{6eeed3d5fbd049d7a7ce9c46a1ed0690,

title = "Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial",

author = "C. Confavreux and P. O'Connor and G. Comi and M.S. Freedman and A.E. Miller and T.P. Olsson and J.S. Wolinsky and T. Bagulho and J.L. Delhay and D. Dukovic and F. Barkhof and P. Truffinet and L. Kappos",

year = "2014",

doi = "https://doi.org/10.1016/S1474-4422(13)70308-9",

language = "English",

volume = "13",

pages = "247--256",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "3",

}

Confavreux, C, O'Connor, P, Comi, G, Freedman, MS, Miller, AE, Olsson, TP, Wolinsky, JS, Bagulho, T, Delhay, JL, Dukovic, D, Barkhof, F, Truffinet, P & Kappos, L 2014, 'Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial', Lancet neurology, vol. 13, no. 3, pp. 247-256. https://doi.org/10.1016/S1474-4422(13)70308-9

TY - JOUR

T1 - Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

AU - Confavreux, C.

AU - O'Connor, P.

AU - Comi, G.

AU - Freedman, M.S.

AU - Miller, A.E.

AU - Olsson, T.P.

AU - Wolinsky, J.S.

AU - Bagulho, T.

AU - Delhay, J.L.

AU - Dukovic, D.

AU - Barkhof, F.

AU - Truffinet, P.

AU - Kappos, L.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1016/S1474-4422(13)70308-9

DO - https://doi.org/10.1016/S1474-4422(13)70308-9

M3 - Article

SN - 1474-4422

VL - 13

SP - 247

EP - 256

JO - Lancet Neurology

JF - Lancet Neurology

IS - 3

ER -